A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Completed · Phase 2 · NCT04718896
Conditions: Moderate to Severe Plaque Psoriasis
At a glance
- Research payments reported, 2025
- $2,145
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 41
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- bimekizumab (drug)
- Dates
- Started 2021-04-06; completion 2025-03-12
- Results posted
- Yes
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
From ClinicalTrials.gov, last updated 2026-08-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $2,145 in research payments for this study in 2025 (1 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dawes Fretzin Clinical Research $2,145
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.